Vol 68, No 5 (2017)
Original paper
Published online: 2017-08-31

open access

Page views 1422
Article views/downloads 1151
Get Citation

Connect on Social Media

Connect on Social Media

Vascular and cardiac function in young adults with classical congenital adrenal hyperplasia

Joanna Wierzbicka-Chmiel, Artur Chmiel, Sławomir Rychlik, Monika Ogrodowczyk-Bobik, Bogdan Marek, Dariusz Kajdaniuk
Pubmed: 28879650
Endokrynol Pol 2017;68(5):505-511.


Introduction: Patients with classical congenital adrenal hyperplasia (CAH) have increased cardiovascular risk, but the vascular and cardiac function during longitudinal corticoids replacement therapy is not known thoroughly.

Material and methods: Cross-sectional study of 19 Caucasian adults with CAH (age 23.7 ± 3.8 years; twelve males) compared to 20 healthy volunteers matched for origin, sex, age, and body mass index (BMI). All of the participants were assessed for flow mediated dilatation of the brachial artery (FMD), intima-media thickness of the common carotid artery (cIMT) and common femoral artery (fIMT), standard echocardiography, and global longitudinal left ventricular function using two-dimensional speckle-tracking echocardiography (LSTE).

Results: The patients with CAH, compared with controls, had decreased FMD (9.4 ± 3.9 vs. 19.8 ± 5.2; p < 0.01), and the difference was still significant after correction for potential confounders. cIMT and fIMT were higher in the CAH group at baseline (for cIMT 0.47 ± 0.4 mm vs. 0.40 ± 0.03 mm; p < 0.01, for fIMT 0.47 ± 0.05 mm vs. 0.41 ± 0.04 mm; p < 0.01) but not after correction for potential confounders. The CAH subjects, compared with controls, had normal or similar left ventricular (LV) ejection fraction and LV mass index. The mean absolute value of LSTE differed in the CAH patients compared with controls (–20.5% ± 1.2 vs. –22.5% ± 1.7; p < 0.01), but it was still within the normal range.

Conclusions: Young adults with CAH and glucocorticoid long-lasting treatment had impaired FMD, an insignificant increase of IMT, and subclinical changes in LV diastolic function in echocardiography.

Article available in PDF format

View PDF Download PDF file


  1. Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet. 2005; 365: 2125–2136.
  2. Mooij C, Kroese J, Claahsen - van der GH, et al. Unfavorable trends in cardiovascular and metabolic risk in pediatric and adult patients with congenital adrenal hyperplasia? Clin Endocrinol. 2010; 73: 137–146.
  3. Sartorato P, Zulian E, Benedini S, et al. Cardiovascular risk factors and ultrasound evaluation of intima-media thickness at common carotids, carotid bulbs, and femoral and abdominal aorta arteries in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2007; 92: 1015–1018.
  4. Kim M, Ryabets-Lienhard A, Dao-Tran A, et al. Increased Abdominal Adiposity in Adolescents and Young Adults With Classical Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency. J Clin Endocrinol Metab. 2015; 100: 1153–1159.
  5. Bonfig W, Schwarz HP. Blood pressure, fludrocortisone dose and plasma renin activity in children with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency followed from birth to 4 years of age. Clin Endocrinol(Oxford). 2014; 81: 871–875.
  6. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Bio. 2003; 23: 168–175.
  7. Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007; 115: 459–467.
  8. Harrington J, Peña AS, Gent R, et al. Adolescents with congenital adrenal hyperplasia because of 21-hydroxylase deficiency have vascular dysfunction. Clin Endocrinol. 2012; 76: 837–842.
  9. Wasniewska M, Balsamo A, Valenzise M, et al. Increased large artery intima media thickness in adolescents with either classical or non-classical congenital adrenal hyperplasia. J Endocrinol Invest. 2013; 36: 12–15.
  10. Amr NH, Ahmed AY, Ibrahim YA. Carotid intima media thickness and other cardiovascular risk factors in children with congenital adrenal hyperplasia. J Endocrinol Invest. 2014; 37: 1001–1008.
  11. Metwalley K, Farghaly H, Sherief T. Left ventricular dysfunction and subclinical atherosclerosis in children with classic congenital adrenal hyperplasia: a single-center study from upper Egypt. Eur J Pediatr. 2015; 175: 405–412.
  12. Mnif MF, Kamoun M, Mnif F, et al. Metabolic profile and cardiovascular risk factors in adult patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Indian J Endocrinol Metab. 2012; 16: 939–946.
  13. Ubertini G, Bizzarri C, Grossi A, et al. Blood Pressure and Left Ventricular Characteristics in Young Patients with Classical Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency. Int J Pediatr Endocrinol. 2009.
  14. Finkielstain GP, Kim MS, Sinaii N, et al. Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2012; 97: 4429–4438.
  15. Schaeffer TL, Tryggestad JB, Mallappa A, et al. An Evidence-Based Model of Multidisciplinary Care for Patients and Families Affected by Classical Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency. Int J Pediatr Endocrinol. 2010.
  16. Ambroziak U, Bednarczuk T, Ginalska-Malinowska M, et al. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency--management in adults. Endokrynol Pol. 2010; 61: 142–155.
  17. Hindmarsh PC. Management of the child with congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol. 2009; 23: 193–208.
  18. Rivkees SA, Crawford JD. Dexamethasone treatment of virilizing congenital adrenal hyperplasia: the ability to achieve normal growth. Pediatrics. 2000; 106: 767–773.
  19. Alberti K, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome--a new worldwide definition. Lancet. 2005; 366: 1059–1062.
  20. Perk J, De Backer G, Gohlke H, et al. European Association for Cardiovascular Prevention & Rehabilitation (EACPR), ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012; 33: 1635–1701.
  21. Sahn DJ, DeMaria A, Kisslo J, et al. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978; 58: 1072–1083.
  22. Roberto M, et al. Lang, Michelle Bierig Chamber quantification. J Am Soc Echocardio. 2005; 18: 1440–1463.
  23. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography. Eur J Echocardio. 2009; 10: 165–193.
  24. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilatation of the brachial artery. A report of the international brachial artery reactivity task force. J Am Coll Cardiol. 2002; 39: 57–265.
  25. Donald A, Halcox J, Charakida M, et al. Methodological Approaches to Optimize Reproducibility and Power in Clinical Studies of Flow-Mediated Dilation. J Am Coll Cardiol. 2008; 51: 1959–1964.
  26. Mizia-Stec K, Gasior Z, Mizia M, et al. Flow-mediated dilation and gender in patients with coronary artery disease: arterial size influences gender differences in flow-mediated dilation. Echocardiography. 2007; 24: 1051–1057.
  27. Spence J. Measurement of Intima-Media Thickness vs. Carotid Plaque: Uses in Patient Care, Genetic Research and Evaluation of New Therapies. Int J Stroke. 2016; 1: 216–221.
  28. Wierzbicka-Chmiel J, Mizia-Stec K, Haberka M, et al. The relationship between cardiovascular risk estimated by use of SCORE system and intima media thickness and flow mediated dilatation in a low risk population. Cardiol J. 2009; 16: 407–412.
  29. Williams RM, Deeb A, Ong KK, et al. Insulin sensitivity and body composition in children with classical and nonclassical congenital adrenal hyperplasia. Clin Endocrinol (Oxford). 2010; 72: 155–160.
  30. Sader MA, Griffiths KA, Skilton MR, et al. Physiological testosterone replacement and arterial endothelial function in men. Clin Endocrinol (Oxford). 2003; 59: 62–67.
  31. Ebenbichler CF, Sturm W, Gänzer H, et al. Flow-mediated, endothelium-dependent vasodilatation is impaired in male body builders taking anabolic-androgenic steroids. Atherosclerosis. 2001; 158: 483–490.
  32. Mizia-Stec K, Wieczorek J, Orszulak M, et al. Flow-mediated dilatation (FMD) and prevalence of cardiovascular risk factors: the value of FMD assessment in high risk patients is limited. Kardiol Pol. 2014; 72: 254–261.
  33. Khazai B, Golden SH, Colangelo LA, et al. Association of endogenous testosterone with subclinical atherosclerosis in men: the multi-ethnic study of atherosclerosis. Clin Endocrinol (Oxford). 2016; 84(5): 700–707.
  34. Voigt JU, Pedrizzetti G, Lysyansky P, et al. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. Eur Heart J Cardiovasc Imaging. 2015; 16(1): 1–11.
  35. Minette M, Hoyer A, Pham P, et al. Cardiac Function in Congenital Adrenal Hyperplasia: A Pattern of Reversible Cardiomyopathy. J Pediatr. 2013; 162(6): 1193–1198.e1.